法洛四联症修复术后肺动脉瓣置换改善结局
本研究基于INDICATOR国际多中心TOF注册队列,采用倾向性评分匹配分析肺动脉瓣置换(PVR)与修复术后法洛四联症(rTOF)患者死亡或持续性室速复合终点的关系。匹配队列中PVR与主要终点风险降低相关(HR 0.41,95%CI 0.21-0.81,P=0.010),亚组分析提示右室显著扩张者获益更明显。
要点
- rTOF患者行PVR与死亡或持续性室速复合终点风险降低相关。
- 右室收缩末期容积指数>80 mL/m2者PVR获益显著。
- 右室收缩末期容积指数≤80 mL/m2者未见显著获益。
核心结论
- 倾向性评分匹配的rTOF患者中,接受PVR者死亡或持续性室速复合终点风险低于未接受PVR者。
研究设计与样本
- 基于INDICATOR国际多中心TOF注册队列,纳入1143例rTOF患者(年龄27±14岁,47%接受PVR,随访8.3±5.2年)。
- 采用倾向性评分1:1匹配(匹配队列n=524)及全队列倾向性评分协变量校正模型分析。
主要发现
- 主要终点(死亡或持续性室速最早发生)在全体1143例中发生82例。
- 匹配队列中PVR vs 无PVR的主要终点校正HR为0.41(95%CI 0.21-0.81;多变量模型P=0.010)。
- 全队列分析结果相似。
- 亚组分析提示右室显著扩张患者获益(交互P=0.046;全队列)。
- 右室收缩末期容积指数>80 mL/m2者PVR与主要终点风险降低相关(HR 0.32;95%CI 0.16-0.62;P<0.001)。
临床怎么用
- 对rTOF患者评估PVR指征时,可结合右室收缩末期容积指数等指标识别可能获益人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of pulmonary valve replacement (PVR) on major adverse clinical outcomes in patients with repaired tetralogy of Fallot (rTOF) is unknown. OBJECTIVES: The purpose of this study was to determine whether PVR is associated with improved survival and freedom from sustained ventricular tachycardia (VT) in rTOF. METHODS: A PVR propensity score was created to adjust for baseline differences between PVR and non-PVR patients enrolled in INDICATOR (International Multicenter TOF Registry). The primary outcome was time to the earliest occurrence of death or sustained VT. PVR and non-PVR patients were matched 1:1 on PVR propensity score (matched cohort) and in the full cohort, modeling was performed with propensity score as a covariate adjustment. RESULTS: Among 1,143 patients with rTOF (age 27 ± 14 years, 47% PVR, follow-up 8.3 ± 5.2 years), the primary outcome occurred in 82. The adjusted HR for the primary outcome for PVR vs no-PVR (matched cohort n = 524) was 0.41 (95% CI: 0.21-0.81; multivariable model P = 0.010). Full cohort analysis revealed similar results. Subgroup analysis suggested beneficial effects in patients with advanced right ventricular (RV) dilatation (interaction P = 0.046; full cohort). In patients with RV end-systolic volume index >80 mL/m2, PVR was associated with a lower primary outcome risk (HR: 0.32; 95% CI: 0.16-0.62; P < 0.001). There was no association between PVR and the primary outcome in patients with RV end-systolic volume index ≤80 mL/m2 (HR: 0.86; 95% CI: 0.38-1.92; P = 0.70). CONCLUSIONS: Compared with rTOF patients who did not receive PVR, propensity score-matched individuals receiving PVR had lower risk of a composite endpoint of death or sustained VT.
引用
- Bokma JP, Geva T, Sleeper LA, et al. Improved Outcomes After Pulmonary Valve Replacement in Repaired Tetralogy of Fallot. J Am Coll Cardiol. 2023. PMID: 37225360. doi:10.1016/j.jacc.2023.02.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。